Alcobra Ltd. (NASDAQ:ADHD) issued its earnings results on Friday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02, MarketWatch Earnings reports.

Alcobra (ADHD) traded up 0.97% on Friday, reaching $1.04. 32,002 shares of the company’s stock traded hands. The stock’s market cap is $28.66 million. The stock has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.16. Alcobra has a 12-month low of $0.83 and a 12-month high of $5.36.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/12/alcobra-ltd-nasdaqadhd-releases-earnings-results-beats-expectations-by-0-02-eps.html.

A number of research analysts have recently commented on the stock. Jefferies Group LLC reissued a “hold” rating and issued a $1.25 price target on shares of Alcobra in a research note on Monday, June 12th. ValuEngine downgraded shares of Alcobra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Friday, June 2nd. Finally, Roth Capital set a $4.00 price objective on shares of Alcobra and gave the company a “buy” rating in a research note on Wednesday, May 31st. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. Alcobra has a consensus rating of “Hold” and an average target price of $1.93.

Alcobra Company Profile

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Earnings History for Alcobra (NASDAQ:ADHD)

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.